Advertisement

aduhelm

Biogen Writes Off Aduhelm Stock

July 22nd, 2022|Categories: Featured, Industry News|Tags: , , , , |

Biogen has written off its remaining Aduhelm inventory in a filing to the Securities and Exchange Commission (SEC) filing. The company declared that its stock of the failed Alzheimer’s drug was functionally worthless, in contrast with a $233 million valuation towards the end of 2021. The remaining stock will be available to patients that are already using the drug, such as those in clinical trials.

Go to Top